1. In patients with DM1 and psoriatic arthritis, high salt intake will lead to an increase in body weight and blood pressure. In patients with psoriatic arthritis that use IL-17 inhibitors, the increase in blood pressure will not take place. 2. In…
ID
Bron
Verkorte titel
Aandoening
hypertension, diabetes type 1, psoriatic arthritis, salt, sodium, blood pressure
hypertensie, diabetes type 1, artritis psoriatica, zout, natrium, bloedddruk
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
- Blood pressure as represented by mean arterial pressure
Doel van het onderzoek
1. In patients with DM1 and psoriatic arthritis, high salt intake will lead to an increase in body weight and blood pressure. In patients with psoriatic arthritis that use IL-17 inhibitors, the increase in blood pressure will not take place.
2. In patients with DM1 and psoriatic arthritis, high salt intake will lead to impaired microcirculatory structure and function, thereby increasing peripheral vessel resistance, leading to increased blood pressure.
3. Nitroglycerin, a endothelial-independent source of nitric oxide, will restore high sodium-induced changes in microcirculation.
4. High sodium intake will lead to an increase or increased activity of Th17 cells and neutrophils in patients with DM1 and psoriatic arthritis whereas we expect this increase to be absent in patients with psoriatic arthritis that use IL-17 inhibitors.
5. High sodium intake will lead to a pro-inflammatory phenotype of monocytes and macrophages in patients with DM1 and psoriatic arthritis.
Onderzoeksopzet
14 days of high salt diet and 14 days of low salt diet.
Onderzoeksproduct en/of interventie
Dietary intervention
After randomization all patients will be asked to adhere to two consecutive (Na+) diets for 14 days each in random order. Thus, total diet period will last four weeks. The 14-day low sodium diet (LSD) consists of a maximum of 3 grams of salt a day, equal to 50 mmol Na+ daily. The 14-day high sodium diet (HSD) consists of a minimum of 12 grams of salt daily, equal to 200 mmol Na+ daily. To check if patients are compliant to the diet, urine Na+ in 24-hours collection will be measured at day 7 and day 11.
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
All patients
- Male between 18 and 40 years of age
- Non-treated office blood pressure < 140/90 mmHg
- A body mass index < 30 kg/m2
- Capable of giving written informed consent and able to comply with the requirements and restrictions listed in the informed consent form
DM1 patients
- Known with Diabetes Mellitus type 1
- With or without microalbuminuria defined as:
o either albuminuria 20-200 mg/L in a morning urine sample
o or albuminuria 30-300 mg/24 hrs collected in a 24-hours urine collection
o or albumin-to-creatinin ratio 2,5-25 mg/mmol in a morning urine sample.
- Stable renal function (creatine clearance > 60 ml/min and < 6 ml/min per year decline)
with or without on stable therapy with RAAS inhibiting agents
- HbA1c levels below 10.0% (86 mmol/mol) during the 6 months preceding the
study
- Multiple injections of insulin a day
Psoriatic arthritis patients without IL-17 inhibitors
- Known with psoriatic arthritis, stable disease activity (mild or in remission) as clinically
assessed by the treating rheumatologist
- Stable renal function (creatinin clearance > 60 ml/min and < 6 ml/min per year decline, no
overt proteinuria)
- Without use of IL-17 inhibitors, IL-10 inhibitors, IL-23 inhibitors, and leflunomide
Psoriatic arthritis patients with IL-17 inhibitors
- Known with psoriatic arthritis, stable disease activity (mild or in remission) as clinically assessed by the treating rheumatologist
- Stable renal function (creatinin clearance > 60 ml/min and < 6 ml/min per year decline, no overt proteinuria)
- Use of IL-17 inhibitors at least 3 months before screening.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- An office blood pressure >140/90 mmHg
- A body mass index > 30 kg/m2
- Use of systemic corticosteroids
- Use of NSAIDS >2 times a week
- A major illness in the past 3 months or any significant chronic medical illness that the Investigator would deem unfavourable for enrolment, including chronic inflammatory diseases, excluding the diseases of interest (DM1 and psoriatic arthritis)
- A history of any type of malignancy within the past 5 years with the exception of successfully treated basal cell cancer of the skin
- A history of any renal disease
- A history of any auto-immune disease other than DM1 and psoriatic arthritis
- A history of cardiovascular disease (in the past 6 months) defined as documented coronary artery disease including myocardial infarction, (un-)stable angina pectoris or acute coronary syndrome, precutenaous transluminal coronary angioplasty, coronary artery bypass grafting, cerebrovascular disease including ischemic and hemorrhagic stroke or a subarachnodial bleeding, or peripheral artery disease including aortic aneurysmata
- A history of eye-surgery, glaucoma or retinal eye disorder
- A history, within 3 years, of drug abuse (including benzodiazepines, opioids, amphetamine, cocaine, THC, methamphetamine)
- A history of alcoholism and/or drinking more than 3 units of alcohol per day. Alcoholism is defined as an average weekly intake of >21 units for males. One unit is equivalent to 8 g of alcohol: a half-pint (~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits
- Smoking or use of tobacco products less then 30 days ago
- Any other issue that in opinion of the Investigator could be harmful to the subject or compromise interpretation of data.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL7479 |
| NTR-old | NTR7721 |
| CCMO | NL63332.018.18 |
| OMON | NL-OMON50531 |